论文部分内容阅读
目的:比较西妥昔单抗(爱必妥)联合FOLFIRI化疗方案与单用FOLFIRI化疗方案治疗转移性结直肠癌患者的临床疗效和毒副反应。方法:回顾性分析2008年1月至2011年11月解放军总医院经组织病理学证实的46例转移性结直肠癌患者临床资料,其中西妥昔单抗联合FOLFIRI化疗方案组22例,单用FOLFIRI方案组24例,观察比较两组方案的近期疗效和不良反应。结果:两组方案治疗转移性结直肠癌的客观缓解率(CR+PR)分别为41.6%和12.5%,其中联合治疗方案治疗效果明显优于单用FOLFIRI化疗方案,两组比较差异有统计学意义(P<0.05)。患者出现的不良反应有痤疮样皮疹、腹泻、骨髓抑制、恶心呕吐、脱发等。除痤疮样皮疹和腹泻外,两组患者毒副反应无显著性差异。结论:西妥昔单抗联合FOLFIRI化疗方案治疗K-Ras基因野生型转移性结直肠癌近期疗效显著,毒副反应较单用FOLFIRI方案无明显增加,患者可以耐受。
Objective: To compare the clinical efficacy and side effects of cetuximab (Erbitux) with FOLFIRI and FOLFIRI alone in the treatment of patients with metastatic colorectal cancer. Methods: The clinical data of 46 patients with metastatic colorectal cancer confirmed by histopathology from January 2008 to November 2011 in PLA General Hospital were retrospectively analyzed. Of them, 22 patients were treated with cetuximab and FOLFIRI chemotherapy alone FOLFIRI program group of 24 cases, observed and compared two groups of short-term efficacy and adverse reactions. Results: The objective response rates (CR + PR) of two groups were 41.6% and 12.5%, respectively, of which the combination therapy was superior to the single FOLFIRI chemotherapy alone. The differences between the two groups were statistically significant Significance (P <0.05). Adverse reactions in patients with acne-like rash, diarrhea, bone marrow suppression, nausea and vomiting, hair loss and so on. In addition to acne-like rashes and diarrhea, two groups of patients with no significant difference in side effects. Conclusion: The efficacy of cetuximab combined with FOLFIRI chemotherapy in the treatment of K-Ras gene wild-type metastatic colorectal cancer is significant. The toxic side effects are not significantly increased compared with FOLFIRI alone, and the patients can tolerate.